Loading... Please wait...

Our Newsletter

ACY-1215 (Rocilinostat) | HDAC6/8 inhibitor

  • ACY-1215 (Rocilinostat).jpg
  • ACY-1215 (Rocilinostat), 400x400px, png
Catalog #:

Product Description

ACY-1215 (Rocilinostat) is an orally-available, hydroxamic acid-based, selective inhibitor of HDAC6 and HDAC8 with IC50 values of 5 nM and 100 nM, respectively. ACY-1215 is12-, 10-, and 11-fold less active against HDAC1, HDAC2, and HDAC3, respecitvely, and has minimal activity (IC50 > 1 uM) against HDAC4, HDAC5, HDAC7, HDAC9, HDAC11, Sirtuin1 and Sirtuin2. [1]

To demonstrate ACY-1215 selectivity for HDAC6, MM.1S cells were cultured with increasing doses of ACY-1215 for 6 hours. Dose-dependent increased acetylated a-tubulin was observed at low doses (0.62 uM) with no effect on histone acetylation.

ACY-1215 has been shown to work synergistically with bortezomib in multiple myeloma models.

Technical information:

Chemical Formula:   C24H27N5O3
CAS #:   1316214-52-4
Molecular Weight:   433.5
Purity:   > 98%
Appearance:   White solid
Chemical Name:   2-(diphenylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)pyrimidine-5-carboxamide
Solubility:   Up to 100 mM in DMSO
Synonyms:   ACY-1215, ACR1215, Rocilinostat

Shipping Condition: The product is shipped in a glass vial at ambient temperature.
Storage condition: For longer shelf life, store solid powder at 4oC desiccated, or store DMSO solution at -20oC.


1. Santo et al., Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood 2012, 119, 2579-2589. Pubmed ID: 22262760

Other Information:

Product Specification (pdf)
MSDS (pdf)
Certificate of Analysis is available upon request.

Write your own product review

Product Reviews

This product hasn't received any reviews yet. Be the first to review this product!

Add to Wish List

Click the button below to add the ACY-1215 (Rocilinostat) | HDAC6/8 inhibitor to your wish list.

You Recently Viewed...